A unique nanoparticle made in a laboratory at
the University of Central Florida is proving promising as a drug
delivery device for treating glaucoma, an eye disease that can cause
blindness and affects millions of people worldwide.
“The nanoparticle can safely get past the blood-brain barrier making
it an effective non-toxic tool for drug delivery,” said Sudipta Seal,
an engineering professor with appointments in UCF’s Advanced Materials
Processing and Analysis Center and the Nanoscience Technology Center.
The findings will be published in an article appearing in the June 28
issue of the Journal of Physical Chemistry C.
Seal and his colleagues from North Dakota State University note in the
article that while barely 1-3 percent of existing glaucoma medicines
penetrate into the eye, earlier experiments with nanoparticles have
shown not only high penetration rates but also little patient
discomfort. The miniscule size of the nanoparticles makes them less
abrasive than some of the complex polymers now used in most eye drops.
Seal and his team created a specialized cerium oxide nanoparticle and
bound it with a compound that has been shown to block the activity of an
enzyme (hCAII) believed to play a central role in causing glaucoma.
The disease involves abnormally high pressure of the fluid inside the
eye, which, if left untreated, can result in damage to the optic nerve
and vision loss. High pressure occurs, in part, because of a buildup of
carbon dioxide inside the eye, and the compound blocks the enzyme that
produces carbon dioxide.
Seal and a team of collaborators including Sanku Mallik, of North
Dakota State University, developed the research on using nanoparticles
as a delivery mechanism for the compound after supervising a student
summer project at UCF. Duke University undergraduate Serge Reshetnikov
spent a summer studying nanoscience on UCF’s Orlando campus as part of
a Research Experience for Undergraduates (REU) project funded by the
National Science Foundation. Reshetnikov started looking into the
possibilities of using nanoparticles as drug delivery tools. Subsequent
research with his advisors led to the specific application for glaucoma.
In their paper on the research, which was also supported by the
National Science Foundation, Seal and Mallik note the results are
“very promising” and that their nanoparticle configuration offers
seemingly limitless possibilities as a non-toxic drug delivery tool.
University of Central Florida